Johnson & Johnson halts development of RSV vaccine in midst of late-stage clinical trials

Janssen, the pharmaceutical division of the Johnson & Johnson companies, announced Wednesday that it will scrap development of a vaccine for respiratory syncytial virus, or RSV, in adults.

from CNN.com - RSS Channel - HP Hero https://ift.tt/TGtxHUp
via IFTTT